Journal: bioRxiv
Article Title: Organelle proteomics reveals novel metabolic vulnerabilities in FLT3-ITD cells
doi: 10.64898/2026.01.19.700272
Figure Lengend Snippet: (A) Heatmap reporting the number of translocating proteins involved in carbohydrate, amino acids, peroxisome and lipid metabolism in FLT3 ITD-JMD and FLT3 ITD-TKD . (B) Bar plot reporting the ΔOCR of basal respiration after the inhibition of glucose usage (UK5099), glutamine usage (BPTES) and lipid usage (ETOMOXIR) for OXPHOS in FLT3 ITD-JMD and FLT3 ITD-TKD in absence and presence of 100nM midostaurin treatment for 24h. (C) Bar plot reporting the percentage of viable cells measured by MTT assay. FLT3 ITD-JMD and FLT3 ITD-TKD were treated with 100nm of midostaurin treatment for 24h either alone or combined with glucose, amino acid and lipid deprivation. (D) Representative immunofluorescence images of FLT3 localization before and after lipid deprivation in both permeabilized and non-permealized FLT3 ITD-JMD and FLT3 ITD-TKD . (E) Barplots showing the percentage of treatment-induced apoptosis (100 * (dead cells after treatment – death cells in control) / viable cells in control) in patient-derived blasts carrying FLT3-ITD in i) the JM domain, ii) both the JM and TK domain and iii) the TK domain upon the indicated treatments. Percentage of apoptotic cells was assessed by Annexin-V labeling.
Article Snippet: Midostaurin (Selleck chemical, S8064) was used at 100 nM for 24 hours.
Techniques: Inhibition, MTT Assay, Immunofluorescence, Control, Derivative Assay, Labeling